Proposed medicine price controls are estimated to result in a loss of about RM8 billion to Malaysia’s medical tourism industry by 2037, according to a cost-benefit analysis.
A cost-benefit analysis estimates T20 patients with private insurance may save RM1.6 billion yearly, four times higher than RM368 million for M40 and 22 times higher than RM73 million for B40.
A cost-benefit analysis finds drug price controls may shutter 2,600 clinics and cause pay cuts, salary freezes, or layoffs of 91,000 to 136,000 private health care jobs.